GlassScriptPhysician profile
Steven Bennett Levy
NPI 1487623427
$4,282.63
in general payments reported to CMS, 2019-2025
27 companies · $120 in 2025
The $120 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $221 · 2020: $96.69 · 2021: $405 · 2022: $1,049 · 2023: $1,004 · 2024: $1,387 · 2025: $120.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,026 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $318 · Consulting Fee: $150 · Education: $16.43.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,026.45 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $318.00 |
| Consulting Fee | $150.00 |
| Education | $16.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $713.15 | 2019-2025 | Parsabiv, Krystexxa, Tavneos |
| Fresenius USA Marketing, INC. | $626.18 | 2019-2024 | Velphoro |
| Becton, Dickinson and Company | $344.00 | 2022-2024 | |
| Otsuka America Pharmaceutical, INC. | $326.42 | 2021-2025 | Jynarque |
| Travere Therapeutics, INC. | $323.16 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $312.98 | 2019-2024 | Farxiga, Lokelma, Evusheld |
| Novartis Pharmaceuticals Corporation | $308.15 | 2019-2025 | |
| Vifor Pharma, INC. | $260.72 | 2020-2024 | Veltassa |
| Glaxosmithkline, LLC. | $177.38 | 2022-2023 | Benlysta |
| Mallinckrodt Hospital Products INC. | $146.09 | 2022-2024 | Acthar |
| Bayer Healthcare Pharmaceuticals INC. | $124.54 | 2022-2024 | |
| Horizon Therapeutics Plc | $114.11 | 2021-2023 | Krystexxa |
| Genzyme Corporation | $79.54 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $79.53 | 2023-2024 | Jardiance |
| Calliditas Therapeutics US INC. | $64.46 | 2023 | Tarpeyo |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aurinia Pharma U.S., INC. | $59.01 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $39.04 | 2022 | |
| Daiichi Sankyo INC. | $30.49 | 2019-2020 | |
| Abbott Laboratories | $20.65 | 2023 | Freestyle Libre 3 |
| Ani Pharmaceuticals, INC. | $19.80 | 2024 | Purified Cortrophin Gel |
| Amicus Therapeutics, INC. | $18.65 | 2023 | Galafold |
| Scpharmaceuticals INC. | $17.75 | 2024 | |
| Akebia Therapeutics INC | $17.56 | 2022 | |
| Opko Pharmaceuticals, LLC | $16.43 | 2023 | Rayaldee |
| Mallinckrodt Enterprises LLC | $15.75 | 2019 | |
| Lilly USA, LLC | $15.16 | 2024 | Jardiance |
| Boston Scientific Corporation | $11.93 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Levy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.